(Reuters) - Alnylam Pharmaceuticals Inc said an early-stage trial of its experimental cholesterol treatment showed the therapy reduced up to half the level of bad cholesterol in patients. The main goal of the study was to test the safety and tolerability of a single dose of the treatment, ALN-PCS -- which works by targeting a specific gene that is associated with high levels of bad cholesterol. ALN-PCS showed a statistically significant gene-silencing rate of 66 percent. ... Credit of the story
No comments:
Post a Comment